Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

Bibliography

• Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004;53:2181-9
   PubMed Web of Science ®Google Scholar
• Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004;47:357-66
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, Orskov C, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002;45:1111-19
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31
   PubMed Web of Science ®Google Scholar
• Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998;47:764-9
   PubMed Web of Science ®Google Scholar
• Ahrén B, Simonsson E, Larsson H, Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Langkopf E, Mark M, 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007;50:6450-3
   PubMed Web of Science ®Google Scholar
• Thomas L, Eckhardt M, Langkopf E, (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-82
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Hauel N, Himmelsbach F, 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg Med Chem Lett 2008;18:3158-62
   PubMed Web of Science ®Google Scholar
• Fuchs H, Tillement JP, Urien S, Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009;61:55-62
   PubMed Web of Science ®Google Scholar
• Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009;30:229-40
   PubMed Web of Science ®Google Scholar
• Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007;81:761-7
   PubMed Web of Science ®Google Scholar
• He H, Tran P, Yin H, Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009;37:536-44
   PubMed Web of Science ®Google Scholar
• Onglyza Prescribing Information. Available from: http://packageinserts.bms.com/pi/pi_onglyza.pdf [last accessed on 12 November 2009]
   Google Scholar
• Retlich S, Withopf B, Greischel A, Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) – investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 2009;30:422-36
   PubMed Web of Science ®Google Scholar
• Dittberner S, Duval V, Staab A, Determination of the absolute bioavailability of BI 1356, a substance with nonlinear pharmacokinetics, using a population pharmacokinetic modelling approach [abstract 1110]. Poster presented at the 16th Annual Meeting of the Population Approach Group in Europe, June 2007, København, Denmark. Available from: www.page-meeting.org/?abstract=1110 [last accessed on 12 November 2009]
   Google Scholar
• He YL, Sadler BM, Sabo R, The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007;46:787-802
   PubMed Web of Science ®Google Scholar
• Hüttner S, Graefe-Mody EU, Withopf B, Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-8
   PubMed Web of Science ®Google Scholar
• Heise T, Graefe-Mody EU, Hüttner S, Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11:786-94
   PubMed Web of Science ®Google Scholar
• Sesoko S, Nakajima M, Hayashi N, Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of the dipeptidyl peptidase 4 inhibitor BI 1356 (linagliptin) in healthy Japanese volunteers [abstract]. Diabetes 2008;57(Suppl 1):A159
   Google Scholar
• Kanada S, Watada H, Hayashi N, Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of BI 1356 (linagliptin), a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetes [abstract]. Diabetes 2008;57(Suppl 1):A158
   Google Scholar
• Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009;328:556-63
   PubMed Web of Science ®Google Scholar
• Linke A, Frank S, Mark M, Klein T. The DPP-4 inhibitor linagliptin (BI 1356) improves wound healing in ob/ob mice [abstract]. Diabetes 2009;58(Suppl 1):A161
   Google Scholar
• Forst T, Uhlig-Laske B, Ring A, The novel, potent, and selective DPP-4 inhibitor BI 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with type 2 diabetes [abstract]. Diabetes 2007;56(Suppl 1):A157
   Google Scholar
• Uhlig-Laske B, Ring A, Graefe-Mody U, DPP-4 inhibitor linagliptin improves glycemic control in type 2 diabetic patients when added to ongoing metformin therapy [abstract]. Diabetes 2009;58(Suppl 1):A143
   Google Scholar
• Horie Y, Hayashi N, Dugi K, Takeuchi M. Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo. Trials 2009;10:82
   PubMedGoogle Scholar
• Graefe-Mody EU, Padula S, Ring A, Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009;25:1963-72
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Friedrich C, Jungnik A, Dugi KA. Lack of pharmacokinetic interactions between the novel DPP-4 inhibitor linagliptin (BI 1356) and pioglitazone in healthy subjects [abstract 13]. Poster presented at 38th Annual Meeting of the American College of Clinical Pharmacology, San Antonio, September 2009
   Google Scholar
• Lankas GR, Leiting B, Roy RS, Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94
   PubMed Web of Science ®Google Scholar
• Reinhold D, Goihl A, Wrenger S, Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 2009;47:268-74
   PubMed Web of Science ®Google Scholar
• O'Brien P, O'Connor BF. Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 2008;1784:1130-45
   Google Scholar